Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Malaria Journal

Figure 2

From: Primaquine: the risks and the benefits

Figure 2

G6PD-deficient red cell survival following daily primaquine dosing. G6PD-deficient red cell survival was assessed by 51Cr labelling and transfusion into G6PD-normal healthy recipients (15 mg/day or 45 mg single dose in Mahidol or Viengchan variants, 30 mg/day Mediterranean variant, and a range of doses in African A- variant). The corresponding haematocrit reductions following continuous dosing (or in the green bar, a single dose) in G6PD-deficient subjects are shown in the inset [17, 2124, 37].

Back to article page